Abstract : We conducted a multicenter, retrospective cohort study of hospitalized patients with serologically proven nephropathia epidemica (NE) living in Ardennes Department, France, during 2000-2014 to develop a bioclinical test predictive of severe disease. Among 205 patients, 45 (22.0%) had severe NE. We found the following factors predictive of severe NE: nephrotoxic drug exposure (p = 0.005, point value 10); visual disorders (p = 0.02, point value 8); microscopic or macroscopic hematuria (p = 0.04, point value 7); leukocyte count >10 × 109 cells/L (p = 0.01, point value 9); and thrombocytopenia <90 × 109/L (p = 0.003, point value 11). When point values for each factor were summed, we found a score of <10 identified low-risk patients (3.3% had severe disease), and a score >20 identified high-risk patients (45.3% had severe disease). If validated in future studies, this test could be used to stratify patients by severity in research studies and in clinical practice.
https://hal-pasteur.archives-ouvertes.fr/pasteur-01834306 Contributor : Jean-Marc ReynesConnect in order to contact the contributor Submitted on : Tuesday, July 10, 2018 - 2:25:25 PM Last modification on : Thursday, April 7, 2022 - 10:10:34 AM Long-term archiving on: : Thursday, October 11, 2018 - 12:50:09 PM
Maxime Hentzien, Stéphanie Mestrallet, Pascale Halin, Laure-Anne Pannet, Delphine Lebrun, et al.. Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission. Emerging Infectious Diseases, Centers for Disease Control and Prevention, 2018, 24 (6), pp.1045 - 1054. ⟨10.3201/eid2406.172160⟩. ⟨pasteur-01834306⟩